Bio-Rad Laboratories (NYSE:BIO.B) is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.
In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows. Researchers in academic institutions, pharmaceutical and biotechnology companies rely on these tools for applications in proteomics, genomics, cell biology and biopharmaceutical process development. Bio-Rad’s innovations, including its digital droplet PCR technology, have been widely adopted for applications that require high sensitivity, precision and reproducibility.
The Clinical Diagnostics segment provides products used by hospitals, reference laboratories and transfusion centers around the world. Offerings include quality control materials, blood grouping and antibody detection reagents, molecular diagnostic assays and automated systems designed to improve the accuracy and efficiency of patient testing. Bio-Rad’s diagnostic solutions support applications such as infectious disease screening, diabetes monitoring and prenatal testing, and are backed by technical service and training to ensure compliance with regulatory standards.
Founded in 1952 and headquartered in Hercules, California, Bio-Rad maintains a broad international footprint with manufacturing sites and sales offices across North America, Europe, Asia-Pacific and Latin America. Over its history, the company has grown through both internal research and development and strategic acquisitions, strengthening its position in critical markets. Bio-Rad continues to invest in product innovation and global expansion to support customers in advancing scientific discovery and delivering reliable clinical results.
